# Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

> **NCT04300244** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Åslaug Helland** · enrollment: 118 (estimated)

## Conditions studied

- Cancer
- Cancer, Lung
- Cancer of Lung
- Mesothelioma
- Mesothelioma; Lung
- Mesothelioma; Pleura
- Mesotheliomas Pleural

## Interventions

- **BIOLOGICAL:** UV1 vaccine + leukine
- **BIOLOGICAL:** ipilimumab
- **BIOLOGICAL:** nivolumab

## Key facts

- **NCT ID:** NCT04300244
- **Lead sponsor:** Åslaug Helland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-04
- **Primary completion:** 2025-03-15
- **Final completion:** 2027-03-15
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04300244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04300244, "Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04300244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*